BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...2018 after a 20-year tenure. At Lilly, Wroblewski contributed to the commercial launch of biologics including Erbitux cetuximab...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

...show an overall survival or progression-free survival benefit in a Phase II trial vs. Erbitux cetuximab...
BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

...cancer; colorectal cancer; skin cancer Blocking endocytosis with DMN inhibitors could enhance the efficacy of cetuximab...
...cell lines. In a xenograft mouse model of cetuximab-resistant SCC, the dynamin inhibitor prochlorperazine plus cetuximab...
...doi:10.1016/j.cell.2020.02.019 CONTACT: Fiona Simpson, University of Queensland, Woolloongabba, Australia email: f.simpson@uq.edu.au Claire Quang Herceptin, trastuzumab (RG597) Erbitux, cetuximab (IMC-C225) Bavencio...
BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

...for colorectal cancer Pfizer Inc. (NYSE:PFE) said FDA approved BRAF inhibitor Braftovi encorafenib plus Erbitux cetuximab...
...Genuair, Eklira Genuair, Tudorza Genuair, Tudorza Pressair, aclidinium bromide (tudorza, LAS34273) BBT-401 LIQ861 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Erbitux, cetuximab (IMC-C225) Opdivo...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Metabolite scavengers to resensitize K-Ras-mutant colorectal cancer to Erbitux

...Colorectal cancer Scavengers of the glycolysis metabolite methylglyoxal could resensitize K-Ras-mutant colorectal cancer to Erbitux cetuximab...
...wild-type K-Ras. In a human G12V K-Ras-mutant CRC cell line, the methylgloxal scavenger carnosine plus Erbitux...
...4, 2020 doi:10.1016/j.celrep.2020.01.012 CONTACT: Akeila Bellahcène, University of Liège, Liège, Belgium email: a.bellahcene@uliege.be Claire Quang Erbitux, cetuximab (IMC-C225) University...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...EGFR/Vδ2 bispecific showed significantly larger reductions in tumor volume vs. Vγ9Vδ2 T cells or Erbitux cetuximab...
BioCentury | Dec 20, 2019
Company News

Regulatory roundup: Gilead, BMS seeking key approvals, plus news about AbbVie, Bavarian Nordic and more

...said FDA granted Priority Review to an sNDA for BRAF inhibitor Braftovi encorafenib plus Erbitux cetuximab...
BioCentury | Oct 24, 2019
Tools & Techniques

Driving safely into solid tumors with CAR exosomes

...from Erbitux cetuximab or Herceptin trastuzumab contained perforin and granzyme B, CAR T-mediated tumor-killing mechanisms. Erbitux...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...company is testing CC-95251 alone and in combination with anti-CD20 mAb rituximab or anti-EGFR mAb cetuximab...
BioCentury | Aug 3, 2019
Finance

Pfizer needs to prove it's a growth story

...Andy Schmeltz on the Monday call. Array intends to seek approval of Braftovi/Mektovi plus Erbitux cetuximab...
Items per page:
1 - 10 of 1094